FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
0:00
4:00
Listen to a soundcast of the July 26, 2021 FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Don't miss an episode of “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” and subscribe to it in the GetPodcast app.